These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11522041)

  • 1. Antibodies against oxidized LDL--theory and clinical use.
    Steinerová A; Racek J; Stozický F; Zima T; Fialová L; Lapin A
    Physiol Res; 2001; 50(2):131-41. PubMed ID: 11522041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
    Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
    Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.
    Palinski W; Hörkkö S; Miller E; Steinbrecher UP; Powell HC; Curtiss LK; Witztum JL
    J Clin Invest; 1996 Aug; 98(3):800-14. PubMed ID: 8698873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.
    Palinski W; Miller E; Witztum JL
    Proc Natl Acad Sci U S A; 1995 Jan; 92(3):821-5. PubMed ID: 7846059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo.
    Shaw PX; Hörkkö S; Tsimikas S; Chang MK; Palinski W; Silverman GJ; Chen PP; Witztum JL
    Arterioscler Thromb Vasc Biol; 2001 Aug; 21(8):1333-9. PubMed ID: 11498462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rethinking oxidized low-density lipoprotein, its role in atherogenesis and the immune responses associated with it.
    Shaw PX
    Arch Immunol Ther Exp (Warsz); 2004; 52(4):225-39. PubMed ID: 15467487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes.
    Freigang S; Hörkkö S; Miller E; Witztum JL; Palinski W
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1972-82. PubMed ID: 9848892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis.
    Matsuura E; Kobayashi K; Tabuchi M; Lopez LR
    Prog Lipid Res; 2006 Nov; 45(6):466-86. PubMed ID: 16790279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
    Cvetkovic JT; Wållberg-Jonsson S; Ahmed E; Rantapää-Dahlqvist S; Lefvert AK
    Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies.
    Virella G; Koskinen S; Krings G; Onorato JM; Thorpe SR; Lopes-Virella M
    Clin Immunol; 2000 May; 95(2):135-44. PubMed ID: 10779407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages.
    Kobayashi K; Tada K; Itabe H; Ueno T; Liu PH; Tsutsumi A; Kuwana M; Yasuda T; Shoenfeld Y; de Groot PG; Matsuura E
    Lupus; 2007; 16(12):929-38. PubMed ID: 18042586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation.
    Seccia M; Albano E; Maggi E; Bellomo G
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):134-40. PubMed ID: 9012648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.
    Ylä-Herttuala S; Palinski W; Butler SW; Picard S; Steinberg D; Witztum JL
    Arterioscler Thromb; 1994 Jan; 14(1):32-40. PubMed ID: 7506053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome.
    Romero FI; Atsumi T; Tinahones FJ; Gómez-Zumaquero JM; Amengual O; Khamashta MA; Hughes GR
    Arthritis Rheum; 1999 Dec; 42(12):2606-11. PubMed ID: 10616007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactivity of IgM and IgG anticardiolipin antibodies with oxidized-low density lipoproteins.
    Damoiseaux J; Jeyasekharan AD; Theunissen R; Tervaert JW
    Ann N Y Acad Sci; 2005 Jun; 1050():163-9. PubMed ID: 16014530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.
    Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P
    Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM.
    Bellomo G; Maggi E; Poli M; Agosta FG; Bollati P; Finardi G
    Diabetes; 1995 Jan; 44(1):60-6. PubMed ID: 7813815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis.
    Romero FI; Khamashta MA; Hughes GR
    Lupus; 2000; 9(3):206-9. PubMed ID: 10805489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus.
    Uusitupa MI; Niskanen L; Luoma J; Vilja P; Mercuri M; Rauramaa R; Ylä-Herttuala S
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1236-42. PubMed ID: 8857919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.